Feb 4 Rockwell Medical said a clinical
study showed that regular administration of its experimental
treatment for iron deficiency reduced the need for additional
agents to boost red blood cell production by 37 percent.
Shares of the company rose as much as 24 percent to $8.03
before the bell.
The company's lead drug, Soluble Ferric Pyrophosphate (SFP),
aims to treat iron deficiency in patients on hemodialysis - the
process of removing wastes and extra fluid from the blood of
patients with kidney failure.
The clinical trial, named Prime, tested the drug in 108
patients to determine whether the drug would demonstrate
efficacy in two ongoing late-stage trials.
Rockwell said it expects efficacy results from the
late-stage studies, codenamed CRUISE-1 and CRUISE-2, in the
second half of the year.
Rockwell's shares closed at $6.45 on the Nasdaq on Friday.